Compare Adobe Systems Inc (ADBE) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs BridgeBio Pharma Inc — how do they compare? Adobe Systems Inc trades at $263.76 (market cap $108.50B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: Adobe Systems Inc is far larger — about 6.5× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | BBIO | |
|---|---|---|
Market Cap | $108.50B | $16.61B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $90.17 |
52-Week Low | $193.41 | $47.29 |
Enterprise Value | $109.94B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.96 exceeding the $5.82 estimate. Revenue grew to $23.77B in 2025, and net income margin improved to 28.69%. However, the stock faces headwinds from AI competition fears and a recent 52-week low, as noted by Citi on April 10, 2026.
The outlook is mixed: robust fundamentals and a 49.2% buy rating from analysts support upside potential, with a consensus price target of $248.86. Key risks include generative AI disruption and CEO transition uncertainty. Investors should weigh strong cash flows against competitive pressures in the software sector.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
